Prognostic criteria in patients with gastrointestinal stromal tumors: a single center experience retrospective analysis

被引:12
|
作者
Tanimine, Naoki [1 ]
Tanabe, Kazuaki [1 ]
Suzuki, Takahisa [1 ]
Tokumoto, Noriaki [1 ]
Ohdan, Hideki [1 ]
机构
[1] Hiroshima Univ, Dept Surg, Grad Sch Biomed Sci, Div Frontier Med Sci,Minami Ku, Hiroshima 7348551, Japan
来源
关键词
gastrointestinal stromal tumor (GIST); prognostic criteria; recurrence; nomogram; adjuvant therapy; C-KIT MUTATION; IMATINIB MESYLATE; TYROSINE KINASE; POOR-PROGNOSIS; DOSE IMATINIB; TRIAL; DIAGNOSIS; PATHOLOGY; RESECTION; SURVIVAL;
D O I
10.1186/1477-7819-10-43
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Gastrointestinal stromal tumors (GISTs) are morphologically and clinically heterogeneous tumors, and their biological behavior is difficult to predict, ranging from clinically benign to malignant. The aim of our study was to reanalyze the value of the commonly used prognostic criteria and recently reported nomogram in predicting disease recurrence in patients with primary resectable GISTs. Methods: The clinicopathological features of 60 patients with GISTs who underwent surgical resection between 1998 and 2010 at Hiroshima University Hospital were retrospectively reviewed. Tumors were classified according to the National Institutes of Health and Armed Forces Institute of Pathology criteria, and nomogram predictions were performed. The relationship between patient and tumor characteristics was tested by univariate analysis using the log-rank test. Furthermore, we assessed nomogram performance with the concordance index and calibration. Results: The median patient follow-up was 4.1 years, with 6 of 60 patients experiencing recurrence. Recurrence was observed only in the high-risk group. The recurrence-free survival (RFS) was 93.0 and 89.9% after 2 and 5 years, respectively. The concordance indices of the nomogram prediction were 0.96 and 0.65 for all patients and the high-risk subgroup, respectively. Calibration of the nomogram-predicted RFS tended to overestimate the recurrence risk relative to the actual RFS. Conclusions: Although the commonly used criteria provide an excellent estimation of tumor behavior, they are limited by prognostic heterogeneity. The predictive nomogram is a beneficial scoring system but not a direct RFS predictor. We need more consideration for small GISTs, particularly those less than 3 cm in diameter, and small GISTs should be analyzed as a subset with potentiality different biological behavior.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Mutational characteristics of gastrointestinal stromal tumors: A single-center analysis of 302 patients
    Liang, Li
    Li, Xin
    Li, Dong
    Liu, Ping
    Nong, Lin
    Dong, Ying
    Liu, Jumei
    Huang, Sixia
    Li, Ting
    ONCOLOGY LETTERS, 2021, 21 (02)
  • [22] The efficacy of preoperative imatinib in locally advanced gastrointestinal stromal tumors: A single-center retrospective analysis
    Mu, M.
    Cai, Z.
    Shen, C.
    Wang, J.
    Zhao, Z.
    Zhang, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S327 - S327
  • [23] Gastrointestinal Stromal Tumor: experience of a single center
    Lupo, L.
    Tedeschi, M.
    Panzera, P.
    Roselli, S.
    de Fazio, M.
    Marzullo, A.
    Piscitelli, D.
    Gentile, A.
    Memeo, V.
    GIORNALE DI CHIRURGIA, 2009, 30 (05): : 102 - 107
  • [24] The analysis of prognostic factors of primary small intestinal gastrointestinal stromal tumors with R0 resection A single-center retrospective study
    Qu, Hui
    Xu, ZhaoHui
    Ren, YanYing
    Gong, ZeZhong
    Ju, Ri Hyok
    Zhang, Fan
    Shao, Shuai
    Chen, XiaoLiang
    Chen, Xin
    MEDICINE, 2022, 101 (25) : E29487
  • [25] Gastrointestinal Stromal Tumors: A Single Institution Experience of 176 Surgical Patients
    Fisher, Sarah B.
    Kim, Steven C.
    Kooby, David A.
    Cardona, Kenneth
    Russell, Maria C.
    Delman, Keith A.
    Staley, Charles A., III
    Maithel, Shishir K.
    AMERICAN SURGEON, 2013, 79 (07) : 657 - 665
  • [26] Efficacy of Sunitinib in Turkish Patients with Gastrointestinal Stromal Tumors; Retrospective Multicenter Experience
    Kefeli, Umut
    Buyukberber, Suleyman
    Akyol, Murat
    Yildiz, Ramazan
    Kaplan, Muhammed Ali
    Ciltas, Aydin
    Sevinc, Alper
    Karaca, Halit
    Seker, Mesut
    Ozdemir, Nuriye
    Alacacioglu, Ahmet
    Coskun, Ugur
    Isikdogan, Abdurrahman
    Dane, Faysal
    Gumus, Mahmut
    Ozkan, Metin
    Suner, Ali
    Tarhan, Mustafa Oktay
    Benekli, Mustafa
    HEPATO-GASTROENTEROLOGY, 2013, 60 (124) : 647 - 652
  • [27] Prognostic Analysis of Duodenal Gastrointestinal Stromal Tumors
    Hong, Liwen
    Zhang, Tianyu
    Lin, Yun
    Fan, Rong
    Zhang, Maochen
    Cheng, Mengmeng
    Zhou, Xiaolin
    Sun, Juntao
    Sun, Peijun
    Wu, Qiangqiang
    Wang, Lei
    Wang, Zhengting
    Zhong, Jie
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2018, 2018
  • [28] Surgery of Upper GI Gastrointestinal Stromal Tumors: Our Experience, Prognostic Analysis
    Kasetsermwiriya, Wisit
    Nagai, Eishi
    Nakata, Kohei
    Nagayoshi, Yosuke
    Shimizu, Shuji
    Tanaka, Masao
    HEPATO-GASTROENTEROLOGY, 2015, 62 (137) : 87 - 92
  • [29] Gastrointestinal stromal tumors - frequency, malignancy, and new prognostic factors: The experience of a single institution
    Bertolini, Valentina
    Chiaravalli, Anna Maria
    Klersy, Catherine
    Placidi, Claudia
    Marchet, Silvia
    Boni, Luigi
    Capella, Carlo
    PATHOLOGY RESEARCH AND PRACTICE, 2008, 204 (04) : 219 - 233
  • [30] Management of gastrointestinal stromal tumors: a single center experience in the pre-Imatinib era
    Jindal, S.
    Singhal, D.
    Kakodkar, R.
    Gupta, S.
    Soin, A.
    Chaudhary, A.
    Nundy, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A162 - A163